Hetlioz Lq (Tasimelteon) Patent Expiration, LOE Window & CMS Spending
Hetlioz Lq (Tasimelteon) by Vanda: FDA Orange Book core substance LOE 2035-02-12 (last listed 2041-02-21), 3 AB generics, $9.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Vanda |
| FDA Application & Pathway | N214517 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-02-12 |
| Last Listed Patent or Exclusivity Date | 2041-02-21 |
| Orange Book Patents (*PED Extensions) | 27 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $9.0M |
| 2024 Medicare Part D Spend | $1.3M |
| 2024 Medicaid Spend | $7.6M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |